Rice Hall James Buys QuidelOrtho Stock

Company Overview - QuidelOrtho reported a total revenue of $2.7 billion and a net income of -$1.1 billion for the trailing twelve months (TTM) [4] - The company's market capitalization stands at $1.6 billion, with shares priced at $23.58 as of February 13, 2026 [4] - The stock has decreased by 43.4% over the past year, underperforming the S&P 500 by 55.2 percentage points [7] Business Model and Operations - QuidelOrtho is a global provider of diagnostic solutions, utilizing a diversified product suite across key healthcare testing segments [6] - The company combines proprietary technology, established distribution, and a broad customer base to enhance scale and recurring revenue [6] - It develops and manufactures diagnostic testing technologies across various areas, including labs, transfusion medicine, point-of-care, and molecular diagnostics [8] - Revenue is generated through direct sales and distributor channels, offering instruments, consumables, and diagnostic tests for both professional and over-the-counter use worldwide [8] Recent Developments - Rice Hall James & Associates, LLC acquired 574,877 shares of QuidelOrtho in the fourth quarter, increasing its stake to 1.3% of the fund's reportable assets under management [2][7] - The acquisition reflects a belief that the stock is undervalued despite QuidelOrtho's inconsistent revenue growth and profitability in recent years [9] - Changes in key leadership positions last year may lead to improving financial results, which could attract value investors [9]